SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 413 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $86,508,106 | +64.2% | 713,646 | +55.1% | 0.01% | +80.0% |
| Q2 2023 | $52,679,658 | -45.6% | 460,004 | -34.6% | 0.01% | -50.0% |
| Q1 2023 | $96,920,677 | +82.2% | 703,190 | +71.3% | 0.01% | +66.7% |
| Q4 2022 | $53,199,847 | +22.8% | 410,556 | +4.7% | 0.01% | +20.0% |
| Q3 2022 | $43,330,000 | +35.5% | 391,981 | -8.1% | 0.01% | +66.7% |
| Q2 2022 | $31,983,000 | -13.8% | 426,649 | -10.2% | 0.00% | -25.0% |
| Q1 2022 | $37,096,000 | +2.3% | 474,864 | +18.0% | 0.00% | +33.3% |
| Q4 2021 | $36,247,000 | -7.9% | 402,528 | -5.4% | 0.00% | -25.0% |
| Q3 2021 | $39,349,000 | +9.5% | 425,489 | -7.9% | 0.00% | 0.0% |
| Q2 2021 | $35,924,000 | -6.8% | 462,103 | -10.6% | 0.00% | 0.0% |
| Q1 2021 | $38,534,000 | -50.7% | 517,016 | +12.7% | 0.00% | -55.6% |
| Q4 2020 | $78,241,000 | +21.4% | 458,920 | +0.0% | 0.01% | 0.0% |
| Q3 2020 | $64,426,000 | -6.6% | 458,768 | +6.7% | 0.01% | -10.0% |
| Q2 2020 | $68,950,000 | +45.5% | 430,022 | -11.2% | 0.01% | +25.0% |
| Q1 2020 | $47,376,000 | -16.9% | 484,312 | +9.6% | 0.01% | 0.0% |
| Q4 2019 | $57,005,000 | +76.6% | 441,757 | +3.1% | 0.01% | +100.0% |
| Q3 2019 | $32,283,000 | -76.3% | 428,633 | -52.2% | 0.00% | -81.0% |
| Q2 2019 | $136,319,000 | +164.3% | 897,131 | +107.3% | 0.02% | +162.5% |
| Q1 2019 | $51,587,000 | -34.4% | 432,821 | -39.9% | 0.01% | -42.9% |
| Q4 2018 | $78,648,000 | +229.8% | 720,691 | +388.1% | 0.01% | +250.0% |
| Q3 2018 | $23,845,000 | -53.6% | 147,638 | -62.0% | 0.00% | -55.6% |
| Q2 2018 | $51,347,000 | +274.9% | 388,467 | +110.2% | 0.01% | +350.0% |
| Q1 2018 | $13,695,000 | +202.3% | 184,845 | +127.0% | 0.00% | +100.0% |
| Q4 2017 | $4,530,000 | -42.4% | 81,428 | -53.0% | 0.00% | 0.0% |
| Q3 2017 | $7,866,000 | +332.4% | 173,428 | +221.6% | 0.00% | – |
| Q2 2017 | $1,819,000 | -26.2% | 53,920 | -35.2% | 0.00% | – |
| Q1 2017 | $2,465,000 | +41.8% | 83,271 | +31.4% | 0.00% | – |
| Q4 2016 | $1,738,000 | -47.1% | 63,349 | +18.5% | 0.00% | -100.0% |
| Q3 2016 | $3,284,000 | -40.2% | 53,481 | -81.4% | 0.00% | 0.0% |
| Q2 2016 | $5,491,000 | +621.6% | 287,871 | +638.2% | 0.00% | – |
| Q1 2016 | $761,000 | -48.9% | 38,995 | +1.0% | 0.00% | – |
| Q4 2015 | $1,490,000 | +177.0% | 38,623 | +130.3% | 0.00% | – |
| Q3 2015 | $538,000 | -57.8% | 16,774 | -59.9% | 0.00% | – |
| Q2 2015 | $1,274,000 | +170.5% | 41,870 | +18.1% | 0.00% | – |
| Q1 2015 | $471,000 | -96.2% | 35,447 | -95.8% | 0.00% | -100.0% |
| Q4 2014 | $12,283,000 | -38.7% | 848,890 | -10.6% | 0.00% | -33.3% |
| Q3 2014 | $20,038,000 | -19.5% | 949,616 | +13.7% | 0.01% | -25.0% |
| Q2 2014 | $24,879,000 | +64.5% | 835,162 | +32.7% | 0.01% | +33.3% |
| Q1 2014 | $15,125,000 | +23.2% | 629,429 | +4.4% | 0.01% | +50.0% |
| Q4 2013 | $12,275,000 | -55.0% | 602,651 | +4.3% | 0.00% | -60.0% |
| Q3 2013 | $27,294,000 | +678.9% | 577,890 | +527.4% | 0.01% | +900.0% |
| Q2 2013 | $3,504,000 | – | 92,115 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
| Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
| Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
| Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
| Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
| Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
| ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
| Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
| Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
| GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |